" class="no-js "lang="en-US"> Limbic - Medtech Alert
Friday, September 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Limbic | Pharmtech Focus

Limbic

About Limbic

Limbic

At Limbic, we believe that information is power. We come from neuroscience, machine learning, software engineering and psychology. Together, we’re using cutting-edge AI and beautiful product design to drive information within psychological therapy. In doing so, we will empower patients and clinicians to tackle the leading cause of disability worldwide. It’s time things changed.

Related Story

Appointments

 Tobias Hauser Joins Limbic to Help Close UK Demand-supply Gap of Psychological Therapy | Pharmtech Focus

Tobias Hauser Joins Limbic to Help Close UK Demand-supply Gap of Psychological Therapy

June 1 2022

Tobias Hauser,  joins Limbic as its Head of Computational Psychiatry. Hauser has worked at the […]